Anders Jönsson, MD, PhD, is today Head of Orthopedic Trauma, Department of Orthopedic Surgery, at the Sahlgrenska University Hospital in Gothenburg, Sweden. He also has a background as Director of Global Medical Science at Stryker, a global orthopedic implant company.
"Anders has very valuable experience and knowledge about the market and product development in orthopedics, both from an industrial perspective as well as from the surgeon's perspective. This is of great value for AddBIO both for discussions with regulatory authorities and with potential partners for the launch of Zolidd", says Dr. Trine Vikinge, CEO AddBIO AB.
Zolidd is a unique biomaterial product enabling enhanced fixation of dental and orthopedic implants through strengthening of the surrounding bone. Bisphosphonate, an approved and since long used class of drugs, is used locally to enhance the implant-bone interface and increase the bone holding power. Better holding power lowers the risk of implant loosening and other complications, thus reducing the need for re-operations and medical expenses. Improved implant stability with Zolidd has been shown in both pre-clinical and clinical models, and two additional clinical studies are on-going. Zolidd is the first product developed from a proprietary technology platform for local drug application from medical implants.
For additional information, please contact Andreas Bunge, CEO Accelerator Nordic AB,
+46 70 824 25 25.
Accelerator Nordic AB is a group of Life Science companies focused on pharmaceutical drug development and medical devices. Accelerator's subsidiaries have exposure towards large growth markets such as medical imaging, oncology and orthopedics. The first medical device products are now on the market and a combination product is in clinical phase. The business model is centered on partnering or out-licensing. Accelerator Nordic is listed on the Aktietorget exchange in Stockholm, Sweden. For more information please see www.acceleratorab.se